Search - tctmd.com

Displaying 381 - 400 of 444

Sort: Relevancy | Date

Presentation

Benefit of Long-term Dual Antiplatelet Therapy (DAPT) in Patients Treated with DES

Presenter: Suresh R. Mulukutla

December 05, 2012

News Daily News

Extended Dual Antiplatelet Therapy Lowers Death, MI Rates in DES Patients

Jason Kahn

December 05, 2012

News Daily News

Meta-analysis Questions Benefit of Longer Dual Antiplatelet Therapy Post-PCI

November 28, 2012

Presentation

Meta-analysis: Clinical Impact of Extended DAPT After PCI in the DES Era

Presenter: S. Cassese

November 26, 2012

News Conference News AHA 2012

No Mortality Benefit with Prolonged Dual Antiplatelet Therapy

November 05, 2012

News Industry News

Study Finds Drug-Eluting Stents Exhibit Some Benefits Over Bare-Metal Stents In Patients Over 80, Though Both Demonstrate Clinical Benefit

October 26, 2012

News Conference News TCT 2012

No Excess Bleeding with EES vs. BMS in Octogenarians Despite Prolonged DAPT

October 26, 2012

Presentation TCT 2012

Proposals for New Short-Term DAPT Use Trials After DES

Presenter: Roxana Mehran

October 25, 2012

Presentation TCT 2012

What Evidence Is Necessary to Shorten DAPT After DES?

Presenter: Fausto Feres

October 25, 2012

News Industry News

Study Finds That Prasugrel May Reduce Cardiovascular Events Among Patients Managed Medically After an Angiogram for Acute Coronary Syndrome

October 24, 2012

News Industry News

PROMUS Element™ and PROMUS Element™ Plus Receive CE Mark Approval for Labeling Update to Include Three-Month Dual Anti-Platelet Therapy

October 24, 2012

News Conference News TCT 2012

Positive Long-Term Results from LEADERS, BioFreedom FIM, ISAR-TEST 5

October 24, 2012

News Conference News TCT 2012

Experts Discuss Need for Development of Next-Generation DES, Insights from Pathology

October 24, 2012

News Conference News TCT 2012

DEBATE-SFA Favors Predilatation with Drug-Eluting Balloon Before BMS

October 24, 2012

News Conference News TCT 2012

DES: The Year in Review

October 23, 2012

News Conference News TCT 2012

DAPT Cessation Within 1 Year Increased Risk for Major Adverse Events

October 23, 2012

Presentation TCT 2012

Rationale and Data for Different DAPT Durations: From 3 to 30 Months (or Longer)

Presenter: David Kandzari

October 22, 2012

Presentation TCT 2012

PARIS 1-Year: Impact of DAPT Cessation and Non-adherence on Adverse Events Following PCI

Presenter: Roxana Mehran

October 22, 2012

Presentation TCT 2012

DAPT Trial Update

Presenter: Laura Mauri

October 22, 2012

News Conference News TCT 2012

Several Trials Highlight DES Comparisons

October 22, 2012

Advertisement

Benefit of Long-term Dual Antiplatelet Therapy (DAPT) in Patients Treated with DES

Extended Dual Antiplatelet Therapy Lowers Death, MI Rates in DES Patients

Meta-analysis Questions Benefit of Longer Dual Antiplatelet Therapy Post-PCI

Meta-analysis: Clinical Impact of Extended DAPT After PCI in the DES Era

No Mortality Benefit with Prolonged Dual Antiplatelet Therapy

Study Finds Drug-Eluting Stents Exhibit Some Benefits Over Bare-Metal Stents In Patients Over 80, Though Both Demonstrate Clinical Benefit

No Excess Bleeding with EES vs. BMS in Octogenarians Despite Prolonged DAPT

Proposals for New Short-Term DAPT Use Trials After DES

What Evidence Is Necessary to Shorten DAPT After DES?

Study Finds That Prasugrel May Reduce Cardiovascular Events Among Patients Managed Medically After an Angiogram for Acute Coronary Syndrome

PROMUS Element™ and PROMUS Element™ Plus Receive CE Mark Approval for Labeling Update to Include Three-Month Dual Anti-Platelet Therapy

Positive Long-Term Results from LEADERS, BioFreedom FIM, ISAR-TEST 5

Experts Discuss Need for Development of Next-Generation DES, Insights from Pathology

DEBATE-SFA Favors Predilatation with Drug-Eluting Balloon Before BMS

DES: The Year in Review

DAPT Cessation Within 1 Year Increased Risk for Major Adverse Events

Rationale and Data for Different DAPT Durations: From 3 to 30 Months (or Longer)

PARIS 1-Year: Impact of DAPT Cessation and Non-adherence on Adverse Events Following PCI

DAPT Trial Update

Several Trials Highlight DES Comparisons

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content